Pfizer Inc (PFE) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.029x

Based on the latest financial reports, Pfizer Inc (PFE) has a cash flow conversion efficiency ratio of 0.029x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.62 Billion) by net assets ($90.40 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check asset allocation strategy of Pfizer Inc to assess the company's strategic physical and investment asset allocation.

Pfizer Inc - Cash Flow Conversion Efficiency Trend (1989–2025)

This chart illustrates how Pfizer Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See PFE net asset value for net asset value and shareholders' equity analysis.

Pfizer Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Pfizer Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Welltower Inc
NYSE:WELL
0.015x
Honeywell International Inc
NASDAQ:HON
0.076x
Pfizer Inc
SA:PFIZ34
0.029x
Intuitive Surgical Inc
NASDAQ:ISRG
0.052x
Uber Technologies Inc
NYSE:UBER
0.103x
Schneider Electric S.E.
PA:SU
0.202x
Deere & Company
NYSE:DE
-0.034x
ALLIANZ SE UNSP.ADR 1/10
F:ALVE
N/A

Annual Cash Flow Conversion Efficiency for Pfizer Inc (1989–2025)

The table below shows the annual cash flow conversion efficiency of Pfizer Inc from 1989 to 2025. For the full company profile with market capitalisation and key ratios, see PFE market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $86.78 Billion $11.71 Billion 0.135x -6.33%
2024-12-31 $88.50 Billion $12.74 Billion 0.144x +47.79%
2023-12-31 $89.29 Billion $8.70 Billion 0.097x -68.07%
2022-12-31 $95.92 Billion $29.27 Billion 0.305x -27.45%
2021-12-31 $77.46 Billion $32.58 Billion 0.421x +85.35%
2020-12-31 $63.47 Billion $14.40 Billion 0.227x +14.37%
2019-12-31 $63.45 Billion $12.59 Billion 0.198x -20.07%
2018-12-31 $63.76 Billion $15.83 Billion 0.248x +8.00%
2017-12-31 $71.66 Billion $16.47 Billion 0.230x -13.50%
2016-12-31 $59.84 Billion $15.90 Billion 0.266x +19.02%
2015-12-31 $65.00 Billion $14.51 Billion 0.223x -5.28%
2014-12-31 $71.62 Billion $16.88 Billion 0.236x +1.67%
2013-12-31 $76.62 Billion $17.77 Billion 0.232x +11.05%
2012-12-31 $81.68 Billion $17.05 Billion 0.209x -14.77%
2011-12-31 $82.62 Billion $20.24 Billion 0.245x +88.78%
2010-12-31 $88.27 Billion $11.45 Billion 0.130x -29.24%
2009-12-31 $90.45 Billion $16.59 Billion 0.183x -41.94%
2008-12-31 $57.74 Billion $18.24 Billion 0.316x +54.05%
2007-12-31 $65.12 Billion $13.35 Billion 0.205x -17.58%
2006-12-31 $70.72 Billion $17.59 Billion 0.249x +12.05%
2005-12-31 $66.36 Billion $14.73 Billion 0.222x -6.40%
2004-12-31 $68.88 Billion $16.34 Billion 0.237x +32.11%
2003-12-31 $65.38 Billion $11.74 Billion 0.180x -64.82%
2002-12-31 $19.95 Billion $10.18 Billion 0.510x +0.80%
2001-12-31 $18.29 Billion $9.26 Billion 0.506x +31.40%
2000-12-31 $16.08 Billion $6.20 Billion 0.385x -60.25%
1999-12-31 $3.15 Billion $3.06 Billion 0.970x +191.62%
1998-12-31 $8.81 Billion $2.93 Billion 0.332x +68.95%
1997-12-31 $8.28 Billion $1.63 Billion 0.197x -33.32%
1996-12-31 $7.00 Billion $2.07 Billion 0.295x -10.02%
1995-12-31 $5.55 Billion $1.82 Billion 0.328x -3.87%
1994-12-31 $4.36 Billion $1.49 Billion 0.341x +5.48%
1993-12-31 $3.90 Billion $1.26 Billion 0.323x +90.52%
1992-12-31 $4.75 Billion $807.00 Million 0.170x +1.36%
1991-12-31 $5.06 Billion $847.60 Million 0.167x -0.33%
1990-12-31 $5.12 Billion $860.50 Million 0.168x +16.84%
1989-12-31 $4.56 Billion $655.80 Million 0.144x --

About Pfizer Inc

NYSE:PFE USA Drug Manufacturers - General
Market Cap
$149.38 Billion
Market Cap Rank
#162 Global
#92 in USA
Share Price
$26.21
Change (1 day)
+1.39%
52-Week Range
$23.12 - $28.55
All Time High
$53.48
About

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret b… Read more